SignPath Pharma, Inc. - FORM 10-K - EX-32.1 - CERTIFICATE OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002. - April 9, 2015

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - SignPath Pharma, Inc.Financial_Report.xls
EX-4.9 - FORM OF CLASS D COMMON STOCK PURCHASE WARRANT - SignPath Pharma, Inc.signpathexh49.htm
EX-10.6 - AMENDMENT DATED APRIL 12, 2012 TO THE LIPSOMAL FOUNDATION MANUFACTURING AGREEMENT WITH POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORCHUNG GMBH. - SignPath Pharma, Inc.signpathexh106.htm
EX-4.10 - FORM OF SERIES D SUBSCRIPTION AGREEMENT - SignPath Pharma, Inc.signpathexh410.htm
EX-31.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A) OR RULE 15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002. - SignPath Pharma, Inc.signpathexh311.htm
EX-10.7 - AMENDMENT, DATED AUGUST 23, 2012, TO THE LIPOSOMAL FORMULATION MANUFACTURING AGREEMENT WITH POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH. - SignPath Pharma, Inc.signpathexh107.htm
EX-10.9 - EXCLUSIVE LICENSE AGREEMENT, DATED JUNE 5, 2013, WITH JOHNS HOPKINS UNIVERSITY. - SignPath Pharma, Inc.signpathexh109.htm
EX-10.16 - AMENDMENT NO. 1, DATED JULY 18, 2014, TO THE SPONSORED RESEARCH AGREEMENT BY AND BETWEEN THE REGISTRANT AND UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH DATED AUGUST 1, 2013. - SignPath Pharma, Inc.signpathexh1016.htm
EX-10.17 - AMENDMENT NO. 1, DATED DECEMBER 12, 2014, TO THE EMPLOYMENT AGREEMENT BY AND BETWEEN THE REGISTRANT AND DR. LAWRENCE HELSON. - SignPath Pharma, Inc.signpathexh1017.htm
EX-10.11 - PATENT AND TECHNOLOGY LICENSE AGREEMENT DATED NOVEMBER 25, 2015, BETWEEN THE REGISTRANT AND THE UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER. - SignPath Pharma, Inc.signpathexh1011.htm
EX-10.15 - SPONSORED RESEARCH AGREEMENT BY AND BETWEEN THE REGISTRANT AND UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH DATED AUGUST 1, 2013. - SignPath Pharma, Inc.signpathexh1015.htm
EX-10.12 - PLACEMENT AGENCY AGREEMENT DATED AS OF SEPTEMBER 17, 2014 BY AND BETWEEN SIGNPATH PHARMA INC. AND MEYERS ASSOCIATES L.P. - SignPath Pharma, Inc.signpathexh1012.htm
10-K - SIGHPATH PHARMA 10K 2014-12-31 - SignPath Pharma, Inc.signpath.htm
EXHIBIT 32.1
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of SignPath Pharma Inc., (the “Company”) on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lawrence Helson, the Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 
1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 
 
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: April 9, 2015
By:
 /s/ Lawrence Helson, M.D
 
Name:
Lawrence Helson, M.D
 
Title:
Chief Executive Officer
   
Chief Financial Officer
   
(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
 
 
 

 
 

SignPath Pharma, Inc. Reports